과제정보
연구 과제 주관 기관 : Sanofi
참고문헌
- Committee for the Korean Guidelines for the Management of Dyslipidemia. 2015 Korean guidelines for the management of dyslipidemia: executive summary (English translation). Korean Circ J 2016;46:275-306. https://doi.org/10.4070/kcj.2016.46.3.275
- Vital Statistics Division, Statistics Korea; Shin HY, Lee JY, Kim JE, Lee S, Youn H, et al. Cause-of-death statistics in 2016 in the Republic of Korea. J Korean Med Assoc 2018;61:573-584. https://doi.org/10.5124/jkma.2018.61.9.573
- Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590. https://doi.org/10.1016/S0140-6736(12)60367-5
- Kim SH, Seo MK, Yoon MH, Choi DH, Hong TJ, Kim HS. Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial. Clin Ther 2013;35:77-86. https://doi.org/10.1016/j.clinthera.2012.11.009
- Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012-1022. https://doi.org/10.1093/eurheartj/ehv043
- Cho YE, Moon PG, Lee JE, Singh TS, Kang W, Lee HC, et al. Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity. Proteomics 2013;13:1257-1275. https://doi.org/10.1002/pmic.201200368
- Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484-493. https://doi.org/10.2183/pjab.86.484
- Young SG, Fong LG. Lowering plasma cholesterol by raising LDL receptors--revisited. N Engl J Med 2012;366:1154-1155. https://doi.org/10.1056/NEJMe1202168
- Enas EA, Kuruvila A, Khanna P, Pitchumoni CS, Mohan V. Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian J Med Res 2013;138:461-491.
- Khang AR, Song YS, Kim KM, Moon JH, Lim S, Park KS, et al. Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes. J Clin Lipidol 2016;10:528-537.e3. https://doi.org/10.1016/j.jacl.2015.12.013
- Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 2011;8:253-265. https://doi.org/10.1038/nrcardio.2011.2
- Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin intolerance. Circulation 2015;131:e389-e391.
- Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci 2015;11:1-23.
- Gulizia MM, Colivicchi F, Arca M, Abrignani MG, Perna GP, Mureddu GF, et al. ANMCO position paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. Eur Heart J Suppl 2017;19 Suppl D:D55-D63. https://doi.org/10.1093/eurheartj/sux020
- Guyton JR, Bays HE, Grundy SM, Jacobson TA; The National Lipid Association Statin Intolerance Panel. An assessment by the statin intolerance panel: 2014 update. J Clin Lipidol 2014;8 Suppl:S72-S81. https://doi.org/10.1016/j.jacl.2014.03.002
- Harrison TN, Hsu JY, Rosenson RS, Levitan EB, Muntner P, Cheetham TC, et al. Unmet patient need in statin intolerance: the clinical characteristics and management. Cardiovasc Drugs Ther 2018;32:29-36. https://doi.org/10.1007/s10557-018-6775-0
- Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. https://doi.org/10.1186/CVM-2-5-205
- Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocrinol Metab 2013;17:977-982. https://doi.org/10.4103/2230-8210.122602
- Sikka P, Kapoor S, Bindra VK, Sharma M, Vishwakarma P, Saxena KK. Statin intolerance: now a solved problem. J Postgrad Med 2011;57:321-328. https://doi.org/10.4103/0022-3859.90085
- Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013;36 Suppl 2:S325-S330. https://doi.org/10.2337/dcS13-2038
- Gluba-Brzozka A, Franczyk B, Toth PP, Rysz J, Banach M. Molecular mechanisms of statin intolerance. Arch Med Sci 2016;12:645-658.
- Kajinami K, McKendrick J, Gandra SR, Cheng L, Hovingh G, Dent R, et al. Management of patients with statin intolerance in Japan, South Korea and Taiwan: comparison of results from a clinician survey. Value in Health 2016;19:A872.
- Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes 2011;4:155-166.
- Stulc T, Ceska R, Gotto AM Jr. Statin intolerance: the clinician's perspective. Curr Atheroscler Rep 2015;17:69. https://doi.org/10.1007/s11883-015-0552-3
- Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015;132:1224-1233. https://doi.org/10.1161/CIRCULATIONAHA.115.018381
- Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379. https://doi.org/10.1136/bmj.g4379
- Ip CK, Jin DM, Gao JJ, Meng Z, Meng J, Tan Z, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. Int J Cardiol 2015;191:138-148. https://doi.org/10.1016/j.ijcard.2015.04.228
- AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267. https://doi.org/10.1056/NEJMoa1107579
- Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol 2015;11:851-855. https://doi.org/10.1517/17425255.2015.1027685
-
Regeneron Pharmaceuticals, Inc. Regeneron announce approval of
$Praluent^{(R)}$ (alirocumab) for the treatment of hypercholesterolemia in Japan [Internet]. New York, NY: PRNewswire; 2016 [accessed on 1 May 2018]. Available from: https://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-approval-of-praluent-alirocumab-for-the-treatment-of-hypercholesterolemia-in-japan-300293422.html. -
Amgen. Amgen's
$Repatha^{(R)}$ (evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol [Internet]. New York, NY: PRNewswire; 2016 [accessed on 1 May 2018]. Available from: https://www.prnewswire.com/news-releases/amgens-repatha-evolocumab-approved-as-first-pcsk9-inhibitor-in-japan-for-the-treatment-of-high-cholesterol-300208360.html. - McDonagh M, Peterson K, Holzhammer B, Fazio S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm 2016;22:641-653q.
- Grundy SM. Dyslipidaemia in 2015: advances in treatment of dyslipidaemia. Nat Rev Cardiol 2016;13:74-75. https://doi.org/10.1038/nrcardio.2015.208
- Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118. https://doi.org/10.1056/NEJMoa1105803
- Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36. https://doi.org/10.1016/S0140-6736(12)60771-5
- Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:758-769. https://doi.org/10.1016/j.jacl.2015.08.006
- Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-2506. https://doi.org/10.1001/jama.2012.25790
- Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-1590. https://doi.org/10.1001/jama.2016.3608
- Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-1819. https://doi.org/10.1056/NEJMoa1316222
- Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-1499. https://doi.org/10.1056/NEJMoa1501031
- Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722. https://doi.org/10.1056/NEJMoa1615664
- Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014;129:1022-1032. https://doi.org/10.1161/CIRCULATIONAHA.113.001292
- Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron H, Marais AD, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a phase 3, single-arm, open-label trial. Atherosclerosis 2015;240:408-414. https://doi.org/10.1016/j.atherosclerosis.2015.03.014
- Turner T, Stein EA. Non-statin treatments for managing LDL cholesterol and their outcomes. Clin Ther 2015;37:2751-2769. https://doi.org/10.1016/j.clinthera.2015.09.004
- Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017;376:1430-1440. https://doi.org/10.1056/NEJMoa1615758
- HPS3/TIMI55-REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217-1227. https://doi.org/10.1056/NEJMoa1706444
- Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017;376:1933-1942. https://doi.org/10.1056/NEJMoa1609581
- Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 2016;10:556-567. https://doi.org/10.1016/j.jacl.2015.12.025
피인용 문헌
- Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Stud vol.11, pp.4, 2020, https://doi.org/10.1007/s13300-020-00778-1
- Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway vol.25, pp.7, 2018, https://doi.org/10.3390/molecules25071529